Correlation of O~6-Methylguanine-DNA Methyltransferase with Prognosis of Malignant Glioblastoma Patients Treated with Temozolomide

WANG Zengguang,YANG Xuejun,PAN Qiang,GAO Song,YANG Shuyuan

DOI: https://doi.org/10.3969/j.issn.1002-0152.2009.06.003

2009-01-01

Abstract:Objective To study MGMT expression level in tumor tissue and examine the effect of MGMT expression on the prognosis of malignant glioma after chemotherapy with temozolomide,to provide clinical evidence for the choice of individual chemotherapy.Methods Sixty patients with pathologically confirmed malignant gliomas were enrolled in this study.The glioma tissues were examined for MGMT protein expression by immunohistochemistry.The patients were divided into two groups according to MGMT expression level.All patients accepted surgical operation,routine radiotherapy and chemotherapy with temozolomide.The progression markers such as free survival time(PFS),image based tumor response and drug safety were evaluated during the follow up period.Results The positive expression of MGMT(-～±) was found in 33 patients,and negative expression(+～++) was found in 27 patients.After 6 treatment courses of TMZ,the objective curative rate in MGMT Negative group was 20/33 which was significantly higher than that in MGMT Positive group(5/27).The average PFST in MGMT Negative group was 18±6.42 months which was significantly longer than that in MGMT Positive group(9.0±1.91 months).Conclusions Curative effect of temozolomide treatment is correlated closely with MGMT expression level in tumor tissue.The assessment of MGMT expression may help doctor to select chemotherapeutic schemes for patients with malignant glioma on individual basis.